{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:14Z","timestamp":1740107414615,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["KSCC1401"],"award-info":[{"award-number":["KSCC1401"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00280-020-04108-x","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T11:28:10Z","timestamp":1596108490000},"page":"285-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase I\/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401)"],"prefix":"10.1007","volume":"86","author":[{"given":"Hironori","family":"Samura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kippei","family":"Ohgaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Kawanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Ureshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Kotaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Shimose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"4108_CR1","unstructured":"The Global Cancer Observatory, International Agency for Research on Cancer 2018. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/10_8_9-Colorectum-fact-sheet.pdf. Accessed 5 Aug 2019"},{"key":"4108_CR2","unstructured":"Services CfCCaI (2018) Projected Cancer Statistics. https:\/\/ganjoho.jp\/en\/public\/statistics\/short_pred.html. Accessed 23 Oct 2018"},{"issue":"10","key":"4108_CR3","first-page":"019","volume":"15","author":"Y Hashiguchi","year":"2019","unstructured":"Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K (2019) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 15(10):019\u201301485","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"4108_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12885-018-4241-9","volume":"18","author":"D Shida","year":"2018","unstructured":"Shida D, Ahiko Y, Tanabe T, Yoshida T, Tsukamoto S, Ochiai H, Takashima A, Boku N, Kanemitsu Y (2018) Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan. BMC Cancer 18(1):334. https:\/\/doi.org\/10.1186\/s12885-018-4241-9","journal-title":"BMC Cancer"},{"issue":"2","key":"4108_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.1205.1113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229\u2013237. https:\/\/doi.org\/10.1200\/JCO.2004.1205.1113(Epub 2003 Dec 1202)","journal-title":"J Clin Oncol"},{"issue":"12","key":"4108_CR6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013\u20132019. https:\/\/doi.org\/10.1200\/JCO.2007.14.9930","journal-title":"J Clin Oncol"},{"issue":"2","key":"4108_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000229787","volume":"77","author":"A Sobrero","year":"2009","unstructured":"Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S, Investigators AT (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77(2):113\u2013119. https:\/\/doi.org\/10.1159\/000229787","journal-title":"Oncology"},{"issue":"14","key":"4108_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417. https:\/\/doi.org\/10.1056\/NEJMoa0805019","journal-title":"N Engl J Med"},{"issue":"3","key":"4108_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/annonc\/mdx1816","volume":"29","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C (2018) S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29(3):624\u2013631. https:\/\/doi.org\/10.1093\/annonc\/mdx1816","journal-title":"Ann Oncol"},{"issue":"36","key":"4108_CR10","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1200\/JCO.2008.5916.7759","volume":"26","author":"HT Arkenau","year":"2008","unstructured":"Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R (2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil\/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 26(36):5910\u20135917. https:\/\/doi.org\/10.1200\/JCO.2008.5916.7759(Epub 2008 Nov 5917)","journal-title":"J Clin Oncol"},{"issue":"1","key":"4108_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/bjc.2011.1201","volume":"105","author":"J Cassidy","year":"2011","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105(1):58\u201364. https:\/\/doi.org\/10.1038\/bjc.2011.1201(Epub 2011 Jun 1014)","journal-title":"Br J Cancer"},{"issue":"4","key":"4108_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3816\/CCC.2006.n.3044","volume":"6","author":"P Tyagi","year":"2006","unstructured":"Tyagi P, Grothey A (2006) Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer 6(4):261\u2013264. https:\/\/doi.org\/10.3816\/CCC.2006.n.3044","journal-title":"Clin Colorectal Cancer"},{"issue":"10","key":"4108_CR13","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds2236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 23(10):2479\u20132516. https:\/\/doi.org\/10.1093\/annonc\/mds2236","journal-title":"Ann Oncol"},{"issue":"2","key":"4108_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.6004\/jnccn.2013.0022","volume":"11","author":"AB Benson 3rd","year":"2013","unstructured":"Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA (2013) Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 11(2):141\u2013152. https:\/\/doi.org\/10.6004\/jnccn.2013.0022(quiz 152)","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"4108_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10147-015-0801-z","volume":"20","author":"T Watanabe","year":"2015","unstructured":"Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K, Japanese Society for Cancer of the C, Rectum (2015) Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20(2):207\u2013239. https:\/\/doi.org\/10.1007\/s10147-015-0801-z","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"4108_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw1206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27(8):1539\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdw1206(Epub 2016 May 1513)","journal-title":"Ann Oncol"},{"issue":"19","key":"4108_CR17","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109\u20133116. https:\/\/doi.org\/10.1200\/JCO.2008.20.6771","journal-title":"J Clin Oncol"},{"issue":"8","key":"4108_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.2010.1031.1936","volume":"29","author":"N Moosmann","year":"2011","unstructured":"Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermuller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V (2011) Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104\u2013a randomized trial of the German AIO CRC study group. J Clin Oncol 29(8):1050\u20131058. https:\/\/doi.org\/10.1200\/JCO.2010.1031.1936(Epub 2011 Feb 1057)","journal-title":"J Clin Oncol"},{"issue":"3","key":"4108_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/bjc.2011.1594","volume":"106","author":"J Souglakos","year":"2012","unstructured":"Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis C, Kouroussis C, Vamvakas L, Georgoulias V, Polyzos A (2012) Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable\/metastatic colorectal cancer (mCRC). Br J Cancer 106(3):453\u2013459. https:\/\/doi.org\/10.1038\/bjc.2011.1594(Epub 2012 Jan 1012)","journal-title":"Br J Cancer"},{"issue":"4","key":"4108_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/COC.1090b1013e31804b31840bb","volume":"30","author":"YZ Patt","year":"2007","unstructured":"Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A, Lin E (2007) Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol 30(4):350\u2013357. https:\/\/doi.org\/10.1097\/COC.1090b1013e31804b31840bb","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"4108_CR21","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/annonc\/mdt1028","volume":"24","author":"W Schmiegel","year":"2013","unstructured":"Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geissler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U (2013) Capecitabine\/irinotecan or capecitabine\/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol 24(6):1580\u20131587. https:\/\/doi.org\/10.1093\/annonc\/mdt1028(Epub 2013 Mar 1584)","journal-title":"Ann Oncol"},{"issue":"11","key":"4108_CR22","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56(11):2602\u20132606","journal-title":"Cancer Res"},{"issue":"9","key":"4108_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(1010)70181-70189","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853\u2013860. https:\/\/doi.org\/10.1016\/S1470-2045(1010)70181-70189(Epub 72010 Aug 70112)","journal-title":"Lancet Oncol"},{"issue":"4","key":"4108_CR24","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s10637-011-9743-0","volume":"30","author":"Y Yamada","year":"2012","unstructured":"Yamada Y, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Kato K, Hamaguchi T, Shimada Y (2012) Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 30(4):1690\u20131696. https:\/\/doi.org\/10.1007\/s10637-011-9743-0","journal-title":"Invest New Drugs"},{"issue":"11","key":"4108_CR25","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1470-2045(1112)70363-70367","volume":"13","author":"YS Hong","year":"2012","unstructured":"Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW (2012) S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 13(11):1125\u20131132. https:\/\/doi.org\/10.1016\/S1470-2045(1112)70363-70367(Epub 72012 Oct 70310)","journal-title":"Lancet Oncol"},{"key":"4108_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1186\/1471-2407-1114-1883","volume":"14","author":"ST Kim","year":"2014","unstructured":"Kim ST, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS (2014) S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer 14:883. https:\/\/doi.org\/10.1186\/1471-2407-1114-1883","journal-title":"BMC Cancer"},{"issue":"4","key":"4108_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10147-015-0943-z","volume":"21","author":"Y Miyamoto","year":"2016","unstructured":"Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y (2016) S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). Int J Clin Oncol 21(4):705\u2013712. https:\/\/doi.org\/10.1007\/s10147-015-0943-z","journal-title":"Int J Clin Oncol"},{"issue":"9783","key":"4108_CR28","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(2111)60613-60612","volume":"377","author":"TS Maughan","year":"2011","unstructured":"Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377(9783):2103\u20132114. https:\/\/doi.org\/10.1016\/S0140-6736(2111)60613-60612(Epub 62011 Jun 60615)","journal-title":"Lancet"},{"issue":"1","key":"4108_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3816\/CCC.2005.n.016","volume":"5","author":"T Cartwright","year":"2005","unstructured":"Cartwright T, Lopez T, Vukelja SJ, Encarnacion C, Boehm KA, Asmar L (2005) Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5(1):50\u201356. https:\/\/doi.org\/10.3816\/CCC.2005.n.016","journal-title":"Clin Colorectal Cancer"},{"issue":"9582","key":"4108_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0140-6736(07)61086-1","volume":"370","author":"M Koopman","year":"2007","unstructured":"Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FLG, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJL, van Bochove A, Sinnige HAM, Creemers G-JM, Tesselaar MET, Slee PHTJ, Werter MJBP, Mol L, Dalesio O, Punt CJA (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. The Lancet 370(9582):135\u2013142. https:\/\/doi.org\/10.1016\/s0140-6736(07)61086-1","journal-title":"The Lancet"},{"issue":"6","key":"4108_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3816\/CCC.2008.n.052","volume":"7","author":"T Cartwright","year":"2008","unstructured":"Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL Jr, Boehm KA, Asmar L (2008) Results of a phase II trial of cetuximab plus capecitabine\/irinotecan as first-line therapy for patients with advanced and\/or metastatic colorectal cancer. Clin Colorectal Cancer 7(6):390\u2013397. https:\/\/doi.org\/10.3816\/CCC.2008.n.052","journal-title":"Clin Colorectal Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04108-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04108-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04108-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T23:23:22Z","timestamp":1627601002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04108-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4108"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04108-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2020,7,30]]},"assertion":[{"value":"8 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Eiji Oki received lecture fee from Merck Biopharma Co., Ltd., Bayer Yakuhin Japan, Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly, Yakult Honsha Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Akitaka Makiyama reports personal fees from Lily, personal fees from Chugai, personal fees from Takeda, outside the submitted work. Masahito Kotaka reports\u00a0lecturefee from Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Takeda Pharmaceutical Company Limited, Merck Biopharma Co., Ltd., and\u00a0Taiho Pharmaceutical Co., Ltd., outside the submitted work. Hideo Baba reports grants, personal fees and non-financial support from Taiho Pharmaceutical Co., Ltd., grants and non-financial support from Merck Biopharma Co., Ltd., during the conduct of the study; grants, personal fees and non-financial support from Ono Pharmaceutical Co., Ltd., grants, personal fees and non-financial support from Eli Lilly Japan K.K., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants from Shionogi & Co., Ltd., grants from Covidien Japan Inc., grants and non-financial support from Yakult Honsha Co.,Ltd., grants from Shin Nippon Biomedical Laboratories, Ltd., grants from Novartis-pharma K.K., grants from Toyama Chemical Co., Ltd., grants and non-financial support from Johnson & Johnson K.K., outside the submitted work. Other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Ethical Guidelines for Clinical Studies in Japan, and the protocol was approved by the institutional review boards of all participating medical institutions. This study was registered in the UMIN clinical trials registry. (UMIN-CTR number UMIN000023329).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval (include appropriate approvals or waivers)"}},{"value":"The informed consent form stated that the results would be published after completion of the study. Consent of the family is not required at the time of article publication according to Japanese ethical guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}